PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
- Conditions
- MelanomaGliomaThyroid CancerNon-Small Cell Lung CancerMalignant NeoplasmsBrain NeoplasmsColorectal Cancer
- Interventions
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 124
- Registration Number
- NCT05538130
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center 53rd street., New York, New York, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Columbia University Medical Center - Neurological Institute of New York, New York, New York, United States
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05536440
- Locations
- 🇺🇸
Clinilabs, Eatontown, New Jersey, United States
🇺🇸ICON, Salt Lake City, Utah, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT05534789
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
- Conditions
- Healthy ParticipantsBiological Availability
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT05525910
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- Conditions
- Alopecia Areata
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05522556
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5506
- Registration Number
- NCT05520138
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 659
- Registration Number
- NCT05518123
- Locations
- 🇸🇪
University Hospital Uppsala (VO Neuro), Uppsala, Sweden
🇧🇪GZA Ziekenhuizen, Antwerpen, Belgium
🇧🇪AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 401
- Registration Number
- NCT05512819
- Locations
- 🇮🇳
Maulana Azad Medical College and Associated with Lok Nayak Hospital, New Delhi, Delhi, India
🇮🇳Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore, Karnataka, India
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05510245
- Locations
- 🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 633
- Registration Number
- NCT05509400
- Locations
- 🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇬🇧4 Medical Clinical Solutions, Swinton, United Kingdom
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia